Heron Therapeutics (HRTX) Equity Average (2016 - 2025)
Heron Therapeutics (HRTX) has disclosed Equity Average for 13 consecutive years, with $14.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 139.67% year-over-year to $14.6 million, compared with a TTM value of $14.6 million through Dec 2025, up 139.67%, and an annual FY2025 reading of -$9.7 million, up 71.43% over the prior year.
- Equity Average was $14.6 million for Q4 2025 at Heron Therapeutics, up from -$6.2 million in the prior quarter.
- Across five years, Equity Average topped out at $216.4 million in Q1 2021 and bottomed at -$39.0 million in Q3 2024.
- Average Equity Average over 5 years is $20.9 million, with a median of -$2.9 million recorded in 2022.
- The sharpest move saw Equity Average plummeted 9493.56% in 2023, then surged 139.67% in 2025.
- Year by year, Equity Average stood at $98.2 million in 2021, then crashed by 81.66% to $18.0 million in 2022, then tumbled by 271.45% to -$30.9 million in 2023, then dropped by 19.26% to -$36.8 million in 2024, then soared by 139.67% to $14.6 million in 2025.
- Business Quant data shows Equity Average for HRTX at $14.6 million in Q4 2025, -$6.2 million in Q3 2025, and -$27.9 million in Q2 2025.